Brief: ADC Therapeutics Says Initial Safety Run‐In Results From Lotis-5 Phase 3 Trial Demonstrate ORR Of 75% & 40% CR Rate With No New Safety Signals
22/09/2022 24:06
Sept 21 (Reuters) - ADC Therapeutics SA ADCT.N :
* INITIAL SAFETY RUN‐IN RESULTS FROM LOTIS-5 PHASE 3 TRIAL
DEMONSTRATE ORR OF 75% AND 40% CR RATE WITH NO NEW SAFETY
SIGNALS
* CAMI PIVOTAL PHASE 2 DATA TO BE HIGHLIGHTED IN ENCORE ORAL
AND
POSTER PRESENTATIONS
Source text for Eikon: ID:nBw4vH1wTa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million